You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 800 A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors

Article metrics

Article menu

Download PDFPDF

Late-breaking abstracts
Clinical trials in-progress
800 A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: November 2020 to March 2024

AbstractFullPdf
Nov 2020176012
Dec 20207604
Jan 20212805
Feb 20212004
Mar 20212208
Apr 20217409
May 20212008
Jun 20210016
Jul 2021004
Aug 2021008
Sep 2021007
Oct 202134026
Nov 202128018
Dec 20211603
Jan 20221409
Feb 20222402
Mar 20225805
Apr 20224606
May 20223805
Jun 20223401
Jul 20223201
Aug 202238014
Sep 20225807
Oct 20224404
Nov 20223809
Dec 20222604
Jan 20234007
Feb 20234801
Mar 20234809
Apr 20233201
May 20232205
Jun 20232601
Jul 20231404
Aug 2023401
Sep 20232800
Oct 20231802
Nov 20234605
Dec 20232201
Jan 20242000
Feb 20241801
Mar 20241200
Total13420237